智通财经APP获悉，宜明昂科-B(01541)再涨超5%，月内累计涨幅已近80%，截至发稿，涨2.64%，报10.88港元，成交额2021.22万港元。
消息面上，宜明昂科近日公布，连同Instil Bio, Inc.宣布IMM2510/AXN-2510的临床最新情况及未来计划。预计将于今年第三季度在内地完成IMM2510/AXN-2510联合化疗治疗一线NSCLC患者的2期试验的约60名患者入组，而2期试验的初步安全性及有效性结果预计将于今年下半年公布。3期试验预计明年年中在内地启动，目前尚待与监管部门商讨。
值得注意的是，5月7日，宜明昂科宣布，就其2024年8月1日与Instil Bio, Inc对IMM2510及IMM27M达成的授权及合作，鉴于临床合作开发的顺利且快速的推进，已如期收到第二笔近期付款500万美元。随着第二笔近期付款500万美元顺利到账，该项目累计收款金额已高达2000万美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.